Literature DB >> 16808994

The use of IRES-based bicistronic vectors allows the stable expression of recombinant G-protein coupled receptors such as NPY5 and histamine 4.

C Allera-Moreau1, P Chomarat, V Audinot, F Cogé, M Gillard, Y Martineau, J A Boutin, A-C Prats.   

Abstract

Stable expression of G protein coupled receptors in cell lines is a crucial tool for the characterization of the molecular pharmacology of receptors and the screening for new antagonists. However, in some instances, many difficulties have been encountered to obtain stable cell lines expressing functional receptors. Here, we addressed the question of vector optimization to establish cell lines expressing the human neuropeptide Y receptor 5 (NPY5-R) or histamine receptor 4 (HH4R). We have compared bicistronic vectors containing viral or cellular internal ribosome entry sites (IRES), co-expressing the receptor and the neomycine resistance gene from a single mRNA, to a bigenic vector containing two distinct promoters upstream each different genes. This study is the first one to validate the use of three cellular IRESs for long-term transgene expression. Our results demonstrate for both NPY5-R and HH4R that the bicistronic vectors with EMCV, VEGF, FGF1A or FGF2 IRES provide clones expressing functional receptors with yields between 25% and 100%. In contrast, the bigenic vector provided no functional clones, related to a low expression of NPY5R mRNA. The cell lines expressing active receptor were stable after more than 50 passages. These data indicate that IRES-based bicistronic vectors are particularly appropriate to establish cell clones expressing active G-coupled protein receptors with a high yield. In the case of NPY5, it was a new way to produce such a stable cell line. Furthermore, the characteristics-presented herein-of this receptor pharmacological property are perfectly in line with those reported in the literature.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16808994     DOI: 10.1016/j.biochi.2006.05.019

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  5 in total

1.  Construction strategies for developing expression vectors for recombinant monoclonal antibody production in CHO cells.

Authors:  Yan-Mei Li; Zheng-Wei Tian; Dan-Hua Xu; Xiao-Yin Wang; Tian-Yun Wang
Journal:  Mol Biol Rep       Date:  2018-09-06       Impact factor: 2.316

Review 2.  Internal ribosome entry site-based vectors for combined gene therapy.

Authors:  Edith Renaud-Gabardos; Fransky Hantelys; Florent Morfoisse; Xavier Chaufour; Barbara Garmy-Susini; Anne-Catherine Prats
Journal:  World J Exp Med       Date:  2015-02-20

3.  Therapeutic Benefit and Gene Network Regulation by Combined Gene Transfer of Apelin, FGF2, and SERCA2a into Ischemic Heart.

Authors:  Edith Renaud-Gabardos; Florence Tatin; Fransky Hantelys; Benoît Lebas; Denis Calise; Oksana Kunduzova; Bernard Masri; Françoise Pujol; Pierre Sicard; Philippe Valet; Jérôme Roncalli; Xavier Chaufour; Barbara Garmy-Susini; Angelo Parini; Anne-Catherine Prats
Journal:  Mol Ther       Date:  2017-11-16       Impact factor: 11.454

4.  Long term expression of bicistronic vector driven by the FGF-1 IRES in mouse muscle.

Authors:  Camille Allera-Moreau; Aurélie Delluc-Clavières; Caroline Castano; Loïc Van den Berghe; Muriel Golzio; Marc Moreau; Justin Teissié; Jean-François Arnal; Anne-Catherine Prats
Journal:  BMC Biotechnol       Date:  2007-10-28       Impact factor: 2.563

5.  A DNA vaccine encoding mutated HPV58 mE6E7-Fc-GPI fusion antigen and GM-CSF and B7.1.

Authors:  He Wang; Jiyun Yu; Li Li
Journal:  Onco Targets Ther       Date:  2015-10-23       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.